Evaluation of the Efficacy of Methylene Blue Administration in SARS-CoV-2-Affected Patients: A Proof-of-Concept Phase 2, Randomized, Placebo-Controlled, Single-Blind Clinical Trial

Evaluation of the Efficacy of Methylene Blue Administration in SARS-CoV-2-Affected Patients: A Proof-of-Concept Phase 2, Randomized, Placebo-Controlled, Single-Blind Clinical Trial

The SARS-CoV-2 pandemic has revolutionized the scientific and medical world in recent years. Methylene blue (MB) is a well-known molecule. The aim of our study was to assess the efficacy of MB against early-phase SARS-CoV-2 infections. All patients with a positive swab for SARS-CoV-2 were eligible f...

Full description

Saved in:
Bibliographic Details
Main Authors: Beatrice Barda, Bruno Di Mari, Emiliano Soldini, Claudia Di Bartolomeo, Maurizia Bissig, Adriana Baserga, Antonella Robatto, Lorenzo Magenta, Rossella Forlenza, Andreas Cerny
Format: Article
Language:English
Published: MDPI AG 2024-10-01
Series:Scientia Pharmaceutica
Subjects:
methylene blue 2
COVID-19 3 SARS-CoV-2
Online Access:https://www.mdpi.com/2218-0532/92/4/56
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2218-0532/92/4/56

Similar Items